Walleye Capital LLC Purchases 10,528 Shares of Werewolf Therapeutics, Inc. (NASDAQ:HOWL)

Walleye Capital LLC raised its stake in Werewolf Therapeutics, Inc. (NASDAQ:HOWL) by 10.7% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 108,968 shares of the company’s stock after purchasing an additional 10,528 shares during the period. Walleye Capital LLC owned 0.24% of Werewolf Therapeutics worth $231,000 as of its most recent SEC filing.

A number of other hedge funds have also recently made changes to their positions in the business. American Century Companies Inc. boosted its stake in Werewolf Therapeutics by 50.7% in the second quarter. American Century Companies Inc. now owns 37,634 shares of the company’s stock valued at $92,000 after acquiring an additional 12,656 shares during the last quarter. SG Americas Securities LLC purchased a new position in Werewolf Therapeutics in the 3rd quarter worth approximately $29,000. Point72 DIFC Ltd purchased a new position in shares of Werewolf Therapeutics in the second quarter worth about $34,000. Rhumbline Advisers purchased a new stake in Werewolf Therapeutics during the 2nd quarter valued at $79,000. Finally, Acadian Asset Management LLC increased its stake in shares of Werewolf Therapeutics by 22.8% during the second quarter. Acadian Asset Management LLC now owns 212,296 shares of the company’s stock valued at $516,000 after buying an additional 39,413 shares during the period. 64.84% of the stock is currently owned by institutional investors and hedge funds.

Werewolf Therapeutics Trading Up 0.5 %

NASDAQ HOWL opened at $1.86 on Wednesday. The company has a fifty day simple moving average of $2.16 and a two-hundred day simple moving average of $2.44. The stock has a market cap of $82.89 million, a P/E ratio of -1.22 and a beta of 0.30. Werewolf Therapeutics, Inc. has a 12-month low of $1.58 and a 12-month high of $8.19. The company has a current ratio of 10.10, a quick ratio of 10.10 and a debt-to-equity ratio of 0.29.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reiterated a “buy” rating and set a $15.00 target price on shares of Werewolf Therapeutics in a report on Tuesday, November 19th.

About Werewolf Therapeutics

Werewolf Therapeutics, Inc, a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies.